Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 126,730

Document Document Title
WO/2017/101808A1
The present invention relates to a benzodiazepine derivative having formula (I) and acting as a short-acting anesthetic, a pharmaceutical composition including the benzodiazepine derivative, a drug kit including the benzodiazepine deriva...  
WO/2017/102712A1
A synthetic nutritional composition comprising choline for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual ...  
WO/2017/105237A1
The present disclosure relates to the use of 2-iminobiotin for treating brain cell injury, in particular in adults. The treatment may be used for the treatment of cerebral hypoxia-ischemia and/or reperfusion injury, including one or more...  
WO/2017/097291A1
The invention relates to the field of analgesics. According to the invention, a kit or a composition, particularly a pharmaceutical composition or a pharmaceutical kit, is provided, comprising a nanocarrier which contains a highly branch...  
WO/2017/098731A1
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or prophylactic agent for diseases associated with abnormalities in mitochondrial functions, such...  
WO/2017/100591A1
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compou...  
WO/2017/096431A8
This invention relates to peptides and their use for modulating sodium channels. More particularly, the present invention relates to peptides and their use in methods of enhancing Nav1.1 activity and for treating or preventing conditions...  
WO/2017/100125A1
This invention generally relates to medicine, pain control and cell biology. In particular, provided are methods for increasing levels of and/or upregulating the expression of ApoA-1 Binding Protein (APOA1 BP, AIBP, or A1-BP) to treat, a...  
WO/2017/097217A1
The present invention provides compounds of general formula (I), and cis-trans-isomers, enantiomers, diastereoisomers, racemates, solvates, hydrates, or pharmaceutically acceptable salts and esters thereof, a preparation method thereof, ...  
WO/2017/098073A1
The present invention relates to oxindole-pirazolo[3,4-b]pyridinone derivatives that act as modulators of protein kinase activated by AMP (AMPK), and to the use thereof for the treatment and prevention of diseases or disorders regulated ...  
WO/2017/096431A1
This invention relates to peptides and their use for modulating sodium channels. More particularly, the present invention relates to peptides and their use in methods of enhancing Nav1.1 activity and for treating or preventing conditions...  
WO/2017/100624A1
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety, and sleep disorders and CNS disorders comprising the administration of a neurotoxin.  
WO/2017/100726A1
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the presen...  
WO/2017/098467A1
The present disclosure relates to method of modulating autophagy by modulators of autophagy, wherein the autophagy includes but is not limited to macroautophagy, chaperone mediated autophagy and microautophagy. The present disclosure fur...  
WO/2017/096963A1
The present invention discloses a use in which an agonist, cGAMP, of key target proteins, stimulator of interferon genes (STING), in the existing immune pathway, and its derivatives are used in preparing a drug of a neurodegenerative dis...  
WO/2017/098733A1
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which exhibits an effect of significant inhibition on cell death induced in cells of patients with diseases associated with abnormalities in...  
WO/2017/100593A1
Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions ...  
WO/2017/100632A1
The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI) and/or susceptibility to neurodegenerative disease in a subject.  
WO/2017/098514A1
Disclosed a method of treating a disease or a disorder characterized by protease activity. A pharmaceutical composition for treating a disease or a disorder characterized by protease activity is further disclosed. A method of detecting a...  
WO/2017/098367A1
The present invention relates to pyrazolopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, wherein X, R1, R2...  
WO/2017/100062A1
Aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents. More particularly, aspects described herein relate to improved methods for infusing food and beverage composit...  
WO/2017/100599A1
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compou...  
WO/2017/099246A1
The present invention provides a transdermally absorbable preparation which is configured such that a medicine-containing adhesive layer is formed on a support material, wherein the adhesive layer contains at least a thermoplastic elasto...  
WO/2017/097728A1
The present invention relates to a compound of formula (I), wherein Het Ar is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted b...  
WO/2017/094838A1
By using a fluorescent ligand for a retinoid X receptor (RXR), said ligand being indicated by one of the following formulas (1)-(3), an evaluative test of ability to bind with RXR can be easily performed. (In the formulas, R1 is methyl, ...  
WO/2017/095734A1
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxymorphone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal...  
WO/2017/095214A1
The present invention relates to a solid, orally-administered veterinary pharmaceutical composition comprising: a) a drug selected from gabapentin and/or fluoxetine or a pharmaceutically acceptable salt of said drugs, preferably gabapent...  
WO/2017/095489A1
This invention generally relates to a composition and method for inducing the expansion and/or regeneration of CD34-positive adult stem cell population, which is useful for developing drugs/vaccines and/or therapies against a variety of ...  
WO/2017/093519A1
The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating an...  
WO/2017/093449A1
A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 1...  
WO/2017/093807A8
The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive ...  
WO/2017/096298A1
Provided herein are compounds that act as histone deacetylase (HDAC) inhibitors, and can affect expression of genes in vivo and in vitro. These HDAC inhibitors are generally volatile compounds that can be administered as a gas or vapor. ...  
WO/2017/095237A1
The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to prot...  
WO/2017/095458A1
This invention generally relates to a composition and method of using recombinant microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA) as therapeutic drugs for treating Alzheimer's diseases (AD). More specifically, the present...  
WO/2017/095904A1
Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin ...  
WO/2017/093718A1
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatingenzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin S...  
WO/2017/093897A1
Compositions comprising an antioxidant directed or indirectly conjugated to an aromatic-cationic peptide are provide. Said antioxidants are selected from TEMPO, Tro, PBN, AHDP, DBHP, Caf and Hem and may be conjugated to the aromatic-cati...  
WO/2017/093060A1
A medium-chain triglyceride (MCT) or medium-chain fatty acid (MCFA) for use in improving cognition which has been impaired by UBE3A deficiency.  
WO/2017/095759A1
In its many embodiments, the present invention provides certain C5-C6-carbocyclic fused iminothiazine dioxide compounds, including compounds Formula (I): and tautomers thereof, and pharmaceutically acceptable salts of said compounds and ...  
WO/2017/093363A1
The present invention is directed to a compound for use in the prevention or treatment of a neurodegenerative disease, in particular of a synucleinopathy. The present invention further is directed to a pharmaceutical composition containi...  
WO/2017/093807A1
The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive ...  
WO/2017/092638A1
The present invention relates to an opioid receptor antagonist derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to a naloxone derivative as shown by general formula (I) ...  
WO/2017/093890A1
The present invention relates to a pharmaceutical composition comprising clobazam or its pharmaceutically acceptable salt(s) or solvate(s) thereof of defined particle size and one or more pharmaceutically acceptable excipients.  
WO/2017/090716A1
The present invention provides type I crystals and type II crystals of 4-(2,5-dimethylpyrimidin-4-yl)-N-(6-fluoro-2-phenyl-[1,2,4]t riazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxami de that have an exceptional phosphodiesteras...  
WO/2017/088755A1
Disclosed hereinis an aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity, comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof. The aminopyrimidine heterocyclic ...  
WO/2017/088731A1
The present invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof, and pharmaceutical compositions containing these compounds. The compounds or the pharmaceutical compositions are used for antagonizing orexin re...  
WO/2017/088723A1
The present invention relates to a class of substituted triazolopiperazine compounds represented by general formula (I), tautomers, enantiomers, diastereomers, racemates, metabolites, metabolic precursors, and pharmaceutically acceptable...  
WO/2017/091661A1
The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to...  
WO/2017/088177A1
The present invention discloses a use of mussel adhesive proteins or a preparation thereof in preventing and suppressing a neuronal inflammation, and particularly discloses a use of mussel adhesive proteins or a preparation thereof in ne...  
WO/2017/089892A1
The present application relates to a compound of Formula (I), and to uses thereof, such the treatment of a neurological or psychoartic disorder.  

Matches 551 - 600 out of 126,730